Enabling access to talicabtagene autoleucel in relapsed/refractory…
A humanized CAR-T therapy approved in India shows successful implementation across multiple centers, potentially expanding access to this treatment for blood cancers globally.
- Lab
- Preclinical
- Early trials
- Late trials
- In practice
Englumafusp alfa plus glofitamab in B cell non-Hodgkin lymphoma
A new combination therapy offers hope for patients with aggressive B-cell lymphomas who don't respond to standard treatments.
Novel or significantly improved treatmentDose-reduced (24 Gy) involved-site radiotherapy combined with…
Lower-dose radiation combined with immunotherapy provided lasting disease control in localized lymphomas, suggesting a gentler approach may work.
Near-term implementable findingSafety and efficacy of immune checkpoint inhibitors as a bridge to…
Immune therapy before stem cell transplant in Hodgkin lymphoma patients showed good survival and disease control without excess side effects.
Standard additionLong-Term Outcomes of Neoadjuvant Chemotherapy (NAC) Prior to…
Neoadjuvant chemotherapy followed by bladder-sparing treatment offered durable remission for some muscle-invasive bladder cancer patients over long term.